These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 8780329)

  • 1. Evolving role of sotalol in the management of ventricular tachyarrhythmias.
    O'Callaghan PA; McGovern BA
    Am J Cardiol; 1996 Aug; 78(4A):54-60. PubMed ID: 8780329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sotalol: An important new antiarrhythmic.
    Anderson JL; Prystowsky EN
    Am Heart J; 1999 Mar; 137(3):388-409. PubMed ID: 10047618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
    Kühlkamp V; Mermi J; Mewis C; Seipel L
    J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical considerations in the use of sotalol for ventricular tachycardia and ventricular fibrillation.
    Campbell RW; Furniss SS
    Am J Cardiol; 1993 Aug; 72(4):80A-85A. PubMed ID: 8346732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
    Lazzara R
    Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs].
    Haverkamp W; Borggrefe M; Block M; Böcker D; Breithardt G
    Z Kardiol; 1996; 85 Suppl 6():97-106. PubMed ID: 9064989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A perspective on the ESVEM trial current knowledge: sotalol should not be the first-line agent in the management of ventricular arrhythmias.
    Garan H
    Prog Cardiovasc Dis; 1996; 38(6):455-6. PubMed ID: 8638026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent.
    Singh BN
    Am J Cardiol; 1996 Aug; 78(4A):41-53. PubMed ID: 8780328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of oral sotalol for sustained ventricular tachyarrhythmias refractory to other antiarrhythmic agents.
    Kehoe RF; MacNeil DJ; Zheutlin TA; Ezri MD; Nazari J; Spangenberg RB; Dunnington C; Lueken M
    Am J Cardiol; 1993 Aug; 72(4):56A-66A. PubMed ID: 8346728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest.
    Haverkamp W; Eckardt L; Borggrefe M; Breithardt G
    Am J Cardiol; 1997 Oct; 80(8A):67G-73G. PubMed ID: 9354413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of the Electrophysiologic Study versus Electrocardiographic Monitoring trial for controlling ventricular tachycardia and fibrillation.
    Reiffel JA
    Am J Cardiol; 1996 Aug; 78(4A):34-40. PubMed ID: 8780327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Class III antiarrhythmic drugs.
    Singh BN; Ahmed R
    Curr Opin Cardiol; 1994 Jan; 9(1):12-22. PubMed ID: 8199363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choice and chance in drug therapy of cardiac arrhythmias: technique versus drug-specific responses in evaluation of efficacy.
    Singh BN
    Am J Cardiol; 1993 Nov; 72(16):114F-124F. PubMed ID: 8237824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Class III antiarrhythmic agents: the next wave.
    Bauman JL
    Pharmacotherapy; 1997; 17(2 Pt 2):76S-83S; discussion 89S-91S. PubMed ID: 9085343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sotalol for ventricular tachyarrhythmias: beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure. ESVEM Investigators. Electrophysiologic Study Versus Electrocardiographic Monitoring.
    Reiffel JA; Hahn E; Hartz V; Reiter MJ
    Am J Cardiol; 1997 Apr; 79(8):1048-53. PubMed ID: 9114762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
    Giorgberidze I; Saksena S; Krol RB; Munsif AN; Kolettis T; Mathew P; Varanasi S; Prakash A; Delfaut P; Lewis CB
    Am J Cardiol; 1997 Sep; 80(5B):3F-9F. PubMed ID: 9291444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrocardiographic predictors in the ESVEM trial: unsustained ventricular tachycardia, heart period variability, and the signal-averaged electrocardiogram.
    Anderson KP; Bigger JT; Freedman RA
    Prog Cardiovasc Dis; 1996; 38(6):463-88. PubMed ID: 8638028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of sotalol in patients with complex ventricular arrhythmias.
    Hohnloser SH; Zabel M; van de Loo A; Klingenheben T; Just H
    Int J Cardiol; 1992 Dec; 37(3):283-91. PubMed ID: 1281807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.